Peptide Association
Start Your Consultation
All peptides
OncologyIn Clinical Trials

Buserelin (Suprefact)

Subcutaneous injection, Intranasal
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Buserelin is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent GnRH agonist. It binds with high affinity to pituitary GnRH receptors, initially stimulating gonadotropin release before inducing receptor desensitization and downregulation, ultimately suppressing sex hormone production.

Mechanism of Action

The peptide is used primarily in the management of hormone-dependent prostate cancer and endometriosis. Structural modifications include substitution of glycine at position 6 with D-serine and replacement of the C-terminal glycine amide with an ethylamide group to enhance potency and duration of action.

Research Summary & Key Findings

Buserelin has been approved in multiple international markets, including Europe and Canada, since the 1980s for prostate cancer and assisted reproductive technology applications, though it is not FDA-approved in the United States. Clinical trials have demonstrated castration rates exceeding 85% in prostate cancer patients, with efficacy comparable to other GnRH agonists. It is available in multiple formulations including subcutaneous depot, intranasal, and subcutaneous injection forms to accommodate different clinical scenarios.

Clinical Status

In Clinical Trials

Buserelin (Suprefact) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injectionIntranasal

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Oncology

Carfilzomib (Kyprolis)

FDA Approved

A tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...

View details

Bortezomib (Velcade)

FDA Approved

A modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...

View details

Lutetium-177 dotatate (Lutathera)

FDA Approved

A radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...

View details

Leuprolide (Lupron) - Oncology

FDA Approved

A GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...

View details

Start Your Consultation

Get an AI-proposed Buserelin (Suprefact) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Buserelin (Suprefact).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.